Kodiak Sciences Inc. (NASDAQ:KOD) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Kodiak Sciences Inc. (NASDAQ:KOD) have received a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $31.1429.

KOD has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $58.00 price target (up from $38.00) on shares of Kodiak Sciences in a report on Friday. Weiss Ratings restated a “sell (e+)” rating on shares of Kodiak Sciences in a research report on Thursday, January 22nd. Finally, UBS Group began coverage on Kodiak Sciences in a research note on Wednesday, January 7th. They set a “buy” rating and a $50.00 target price for the company.

Hedge Funds Weigh In On Kodiak Sciences

Large investors have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC lifted its holdings in Kodiak Sciences by 1,221.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock valued at $28,000 after purchasing an additional 916 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Kodiak Sciences during the fourth quarter worth about $29,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Kodiak Sciences during the 4th quarter worth about $72,000. Strs Ohio acquired a new position in shares of Kodiak Sciences during the 4th quarter worth about $87,000. Finally, Aster Capital Management DIFC Ltd purchased a new position in Kodiak Sciences in the 4th quarter valued at about $119,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Key Kodiak Sciences News

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: GLOW2 Phase 3 topline showed Zenkuda superiority vs. sham, with 62.5% of treated patients achieving a ≥2‑step DRSS improvement vs. 3.3% for sham—supporting efficacy across two Phase 3 studies and setting up a likely BLA submission. Kodiak Sciences Announces Positive Topline Results in GLOW2
• Positive Sentiment: Major news outlets and financial press reported the successful late‑stage readout, triggering broad market buying and coverage that is amplifying investor interest. Reuters: Kodiak Sciences shares surge after eye drug succeeds in late-stage study
• Positive Sentiment: Industry press expects a Biologics License Application (BLA) filing next after the two positive Phase 3 studies, which would move Zenkuda toward regulatory review and potential commercialization. Bioworld: Kodiak’s Zenkuda sparkles in Glow2, BLA filing next
• Neutral Sentiment: Financial outlets and market movers lists highlighted KOD among the biggest gainers after the readout; this increases visibility but also invites short‑term trading and coverage-driven volatility. Seeking Alpha: Kodiak posts trial win
• Neutral Sentiment: Unusual options activity was reported—3,472 put options traded (a ~1,256% increase versus typical daily put volume)—which could reflect hedging by longs or speculative bets and may add intraday implied‑volatility pressure. (No direct article linked)
• Negative Sentiment: After a large one‑day rally the stock is potentially vulnerable to profit‑taking and heightened volatility; KOD has a high beta and a wide gap between current price and longer‑term moving averages, so technical pullbacks are possible.

Kodiak Sciences Stock Up 74.8%

KOD stock opened at $39.76 on Friday. Kodiak Sciences has a 52-week low of $1.92 and a 52-week high of $40.46. The firm has a market cap of $2.11 billion, a P/E ratio of -9.65 and a beta of 2.61. The company’s 50-day simple moving average is $24.95 and its 200-day simple moving average is $21.62.

Kodiak Sciences Company Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.